HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line.
Authors
Fily, FAyikobua, E
Ssemwanga, D
Nicholas, S
Kaleebu, P
Delaugerre, C
Pasquier, E
Amoros Quiles, I
Balkan, S
Schramm, B
Issue Date
2018-07-29Submitted date
2018-08-07
Metadata
Show full item recordAbstract
The number of patients on second-line antiretroviral therapy is growing, but data on HIV drug resistance patterns at failure in resource-constrained settings are scarce. We aimed to describe drug resistance and investigate the factors associated with extensive resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), in patients failing second-line therapy in the HIV outpatient clinic at Arua Regional Referral Hospital, Uganda.Publisher
Wiley-BlackwellPubMed ID
30058269Language
enISSN
1365-3156ae974a485f413a2113503eed53cd6c53
10.1111/tmi.13131
Scopus Count
Collections
Related articles
- Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
- Authors: Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.
- Issue date: 2017 Aug
- Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
- Authors: Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E, MOBIDIP study group.
- Issue date: 2017 Sep
- Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.
- Authors: Villabona-Arenas CJ, Eymard-Duvernay S, Aghokeng A, Guichet E, Toure-Kane C, Bado G, Koulla-Shiro S, Delaporte E, Ciaffi L, Peeters M
- Issue date: 2018 Jun
- HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
- Authors: Jiamsakul A, Sungkanuparph S, Law M, Kantor R, Praparattanapan J, Li PC, Phanuphak P, Merati T, Ratanasuwan W, Lee CK, Ditangco R, Mustafa M, Singtoroj T, Kiertiburanakul S, TREAT Asia Studies to Evaluate Resistance – Monitoring Study (TASER-M).
- Issue date: 2014
- Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
- Authors: Fox MP, Berhanu R, Steegen K, Firnhaber C, Ive P, Spencer D, Mashamaite S, Sheik S, Jonker I, Howell P, Long L, Evans D
- Issue date: 2016 Sep